See every side of every news story
Published loading...Updated

Fulgent Genetics Revenue Tops Estimates @themotleyfool #stocks $FLGT

Summary by The Motley Fool
Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%. Despite a GAAP earnings loss,…

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Stockxpo - A professional network of traders, investors and analysts broke the news in on Friday, February 28, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.